HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- ‘Strategic menu’ of noninvasive options needed to boost colorectal cancer screening rates
-
- Big data in bladder cancer: I call B.S.! Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- New class of inhibitors change treatment paradigm in ALK-positive non-small cell lung cancer
- Progression of clinical exposure, understanding key to advanced practice provider onboarding Janice Shipe-Spotloe, PA-C, MS, DFAAPA, CPAAPA
- Practical considerations must guide combination treatment for older patients with advanced hormone receptor-positive breast cancer Rachel A. Freedman, MD, MPH; Sara M. Tolaney, MD, MPH
- Prognostication in myelofibrosis: Integrating genetics into routine practice Gabriela Hobbs, MD
- Multimodality imaging of sinonasal undifferentiated carcinoma Munir Ghesani, MD, FACNM; Ana M. Franceschi, MD
- Diverse gut microbiota may improve OS in allogeneic hematopoietic cell transplantation
- Cancer centers lack aids to improve sexual dysfunction among survivors
-
- Pembrolizumab induces durable responses in advanced liver cancer
- Obese men at higher risk for recurrence after radical prostatectomy
- Elotuzumab plus stem cell transplant shows promise for multiple myeloma
- CAR T-cell therapy shows efficacy for extramedullary ALL
- Novel drug shows early efficacy for steroid-dependent chronic GVHD
- Ruxolitinib therapy appears safe prior to allogeneic HSCT for myelofibrosis
- Data emerge on new immunotherapeutic targets for melanoma
- Comprehensive follow-up care model stands to serve current, future HSCT survivors
-
- CAR T-cell therapy may serve as bridge to transplantation for ALL
- BRAF/MEK inhibitor therapy a preferred option for metastatic melanoma
- Collaboration key to identification, incorporation of biomarkers for immuno-oncology
- Real-world data can guide decisions about which patients should receive immunotherapy
- High microsatellite instability, mutation load may predict checkpoint inhibitor response
- CAR T-cell therapy holds promise for multiple myeloma
- Survivorship role, responsibility needs a place in multidisciplinary cancer care team
- Chlamydia infection may double risk for ovarian cancer
-
- HER-2 mutations linked to hormone therapy resistance in breast cancer subtype
- Providers less likely to recommend HPV vaccine to boys than girls
- Participation in clinical trials may eliminate ovarian cancer survival disparities
- PARP-7 mutation associated with longer ovarian cancer survival
- Trend of patients acting like consumers will change cancer centers’ strategies
- Incoming Association of Community Cancer Centers president to focus on cancer care team burnout ‘epidemic’
- High-deductible insurance plans linked to delays in breast cancer diagnosis, treatment
- USPSTF endorses behavioral counseling to prevent skin cancer
-
- Minimal residual disease more prognostic than remission in myeloma
- Diffuse myocardial fibrosis may predict diastolic dysfunction in sickle cell anemia
- Hydroxyurea linked to ‘significant, rapid’ reduction of sperm count
- MRI-based prediction model may reduce unnecessary biopsies in prostate cancer
- Savolitinib shows some activity for papillary renal cell carcinoma
- Certain diets increase risk for colorectal cancer
- Cardiovascular adverse events common with carfilzomib
- Depressive symptoms may increase head, neck cancer mortality
-
- Obese, overweight women at increased risk for cervical cancer
- Insurers’ cost for chemotherapy varies across delivery location
- FDA approves Imfinzi for unresectable stage III NSCLC tumors
- FDA grants breakthrough therapy designation to Promacta for severe aplastic anemia
- FDA grants breakthrough therapy designation to erdafitinib for metastatic urothelial carcinoma
- FDA grants priority review to frontline Darzalex for multiple myeloma
- Moderate coffee intake reduces risk for liver cancer, cirrhosis, fibrosis
- Transparent conversations needed across cancer continuum to improve patients’ illness understanding
-
- Biosimilar PF-05280586 equivalent to rituximab for follicular lymphoma
- Opdivo plus Yervoy improves PFS for non-small cell lung cancer with high tumor mutation burden
- American Association for Cancer Research names president-elect
- Prostate cancer expert named co-chair of NCI committee
- Samuel Waxman Cancer Research Foundation to present award
- Fox Chase Cancer Center oncologist to receive lifetime achievement award